Introduction
Asthma remains a common disease that is associated with substantial morbidity. A subset of patients, from 5 to 20%, have severe asthma that causes persistent interference with daily life despite treatment with current, state-ofthe-art medications [1] . Improved understanding of pathogenetic events in asthma has motivated development of new treatments [2] . Description of inflammatory events in the airways has enabled characterization of various disease phenotypes and monitoring of the impacts of drug therapies [3 ,4] . Although these recent advances allow us to customize anti-inflammatory and bronchodilating therapies, as yet there are no widely available treatments that address the remodeling of the airway wall that occurs in asthma (see [5] for an authoritative review of airway remodeling in asthma).
Airway smooth muscle changes in asthma
The potential to develop airflow obstruction is a characteristic and defining feature of asthma [6] . Musclemediated bronchoconstriction causes much of the short-term variability in airflow and many of the day-today symptoms of asthma [7, 8] . In addition to being hyperresponsive, there is excessive accumulation of smooth muscle in asthmatic airway [9] . This accumulation of smooth muscle is a consistent feature of airway remodeling in asthma [5, 10 ]. Unfortunately, anti-inflammatory therapy that controls clinical manifestations of asthma does not reverse airway remodeling [5] .
The changes in airway muscle phenotype and mass are more pronounced in severe asthma [11, 12] . If we are to improve the care we provide to those patients who continue to experience poor control of their disease despite being compliant in their use of standard medications, that is, patients with severe asthma, we need additional new treatment options [13] .
Bronchial thermoplasty
Bronchial thermoplasty is a novel procedure that directly targets airway muscle [14] . Through the direct application of heat, the mass of muscle in the airway wall is reduced [15] . This has dual benefits because it both reverses the accumulation of excess muscle that is part of airway remodeling that contributes to narrowing of the airway lumen and reduces the potential for future dynamic airway narrowing due to bronchoconstriction.
Bronchial thermoplasty is performed at fiberoptic bronchoscopy (FOB). The methods have been described in a number of publications [16] . Three separate procedures are required to treat all accessible airways (excepting the right middle lobe). Although performed under moderate (conscious) sedation in an outpatient setting, bronchial thermoplasty procedures take longer
Purpose of review
The present article will address the potential for bronchial thermoplasty to be used in addition to conventional medications to help us treat our patients with severe asthma.
Recent findings
Two recently published studies report on the use of bronchial thermoplasty in patients with severe asthma. Now that patients with a range of asthma severity have been treated with bronchial thermoplasty, we are better able to comment on the appropriate selection of patients for this therapy that should optimize benefits and limit complications. In addition, studies reporting longer term follow-up are now available indicating the persistence of benefit and the absence of late developing adverse events. 
Bronchial thermoplasty in severe asthma
Since the initial report showing it was feasible to carry out bronchial thermoplasty in patients with asthma, three randomized, controlled trials have reported the safety and efficacy of bronchial thermoplasty: Asthma Intervention Research (AIR), Research in Severe Asthma (RISA), and the AIR2 trials [17] [18] [19] 20 ] . The demographic data on the participants enrolled in these trials are given in Table 1 and show the escalating severity of asthma across the feasibility, AIR, and RISA studies. All four studies provided evidence of benefit following bronchial thermoplasty and the various outcomes are summarized in Table 2 . Patients with severe asthma were enrolled in the RISA and AIR2 trials, which are discussed separately.
Research in Severe Asthma trial
A total of 32 individuals with asthma that remained symptomatic despite treatment with high-dose inhaled corticosteroids (ICSs), other medications including leukotriene antagonists or oral prednisone up to 30 mg/day, and long-acting beta-agonists (LABAs) were randomized to two groups [19] . All received standard medications, whereas the active group (n ¼ 15) underwent bronchial thermoplasty. When evaluated at 22 weeks after treatment, the bronchial thermoplasty group enjoyed better control of their asthma and improved airflow. Because this patient group are at risk of overtreatment, there was a period of protocol-directed reduction in (oral and inhaled) steroid doses between weeks 22 and 36. It was possible to reduce total steroid doses, and although the difference was not statistically significant, steroid reduction was greater in the bronchial thermoplasty group. At 52 weeks, the bronchial thermoplasty group continued to enjoy improved asthma control indicated by less need for rescue bronchodilator, increased asthma quality of life (AQLQ) scores and reduced asthma control questionnaire (ACQ) scores.
Asthma Intervention Research 2 trial
The Asthma Intervention Research 2 (AIR2) trial examined the effects of bronchial thermoplasty in 298 patients with asthma severity that overlapped that in the AIR and RISA trials [20 ] . However, in order to reduce post-procedure deteriorations in asthma requiring hospitalization, the degree of airflow obstruction at baseline was less than that in the RISA trial, and oral prednis(ol)one use at entry was restricted to 10 mg/day or less. Another criterion for inclusion was that patients were persistently affected by asthma. This was indicated by the patients' low percentage of symptom-free days, less than 17%, and the impaired quality of life, mean 4.3 out of maximum score of 7, despite compliance with prescribed medications.
Unlike previous studies of bronchial thermoplasty in asthma, the control group in the AIR2 trial underwent three sham bronchoscopies. In the two previously published randomized studies, the control groups had received usual care with standard medications [18, 19] . This was an important feature of the AIR2 trial design, as it addressed the concern about the placebo effect associated with procedures.
The primary outcome was improvement in AQLQ at 6, 9 and 12 months. Although the absolute differences between groups were small, AQLQ improved to a statistically significant greater extent in the bronchial thermoplasty treated group [21] . When looked at according to how many patients enjoyed a clinically significant improvement in AQLQ score of 0.5, that is, by responder analysis, again the group receiving bronchial thermoplasty had statistically significant superior outcomes [22] . That improvements in the sham-treated group persisted out to 12 months was not expected. The secondary outcomes, including ACQ scores, symptom scores, airflow, airway hyperresponsiveness, and rescue medication use showed a trend toward improvement in the bronchial thermoplasty-treated group, but none were statistically significant. Other outcomes, relating to need for healthcare for deteriorations in asthma control, did show benefits with bronchial thermoplasty.
Risks and benefits of bronchial thermoplasty in severe asthma
As the airways are inflamed and sensitive in asthma, and treatment with bronchial thermoplasty results in some degree of insult to the airway surface and wall contents, side-effects of the procedure are inevitable. In patients with normal airflow at baseline and mild asthma, the procedure is well tolerated. In the feasibility study, there were no serious or severe adverse events and there were no hospitalizations for respiratory events after treatment [17] . The experience in patients with more severe asthma and baseline airflow obstruction differed, as some required admission to hospital for management of respiratory deteriorations in the days following treatment with bronchial thermoplasty [18, 19] . As the spectrum of asthma severity increased across the AIR and RISA trials, so did the severity of adverse events encountered. The incidence of hospitalization increased from nil to six following 155 procedures in AIR, to seven following 45 procedures in RISA. Clearly, it will be appropriate to establish a balance between treating those with the greatest potential for benefit, that is, more severe uncontrolled asthma, against the risks for causing aggravation of asthma symptoms requiring admission to hospital. This was addressed in the AIR2 trial by selecting patients with more reserve than those enrolled in the RISA trial [20 ] . Thus, treating patients on no or modest doses of prednisone ( 10 mg/day), and with less severe impairment of forced expiratory volume in 1 s was associated with low rates of hospitalization in the post-treatment period (see Table 3 ).
Less severe adverse events are common after treatment with bronchial thermoplasty [17] [18] [19] 20 ]. As mentioned above, deploying an instrument to deliver heat to the airway of a patient with asthma can be expected to cause aggravation of airway symptoms. As these symptoms are familiar to patients and are managed with usual strategies, these adverse events, although frequent, are well tolerated. Patients who have completed the treatment with three bronchoscopies have reported a high level of satisfaction and express positive attitudes toward the procedure [23] .
Long-term outcomes
As the intervention is expected to remodel the airway wall (or more correctly to reverse the accumulation of smooth muscle that occurs during remodeling of the airway during chronic asthma), concerns have been raised about the potential for long-term ill effects of bronchial thermoplasty on airway structure and function [24, 25] . Data are becoming available on 5-year outcomes and show that airflow (pre-bronchodilator and post-bronchodilator) is not adversely affected [26] . High-resolution computed tomography scanning has been used to examine airway integrity and the lung tissue surrounding treated airways. To date, 5 years after treatment, no evidence of structural change or damage to airways or to pulmonary parenchyma has been found [26] . Table 3 Treatment period respiratory-related hospitalizations
Number of hospitalizations (number of individuals) Comparison of hospitalizations, events and rates, during the treatment periods -from first procedure to 6 weeks after third procedure -in three randomized trials of bronchial thermoplasty. Selection criteria for the AIR2 trial were modified, based on prior experience in the AIR and RISA trials, to reduce risks of hospitalization after treatment. In the AIR2 trial, participants underwent sham procedures, which led to exacerbation of asthma symptoms in two participants, requiring hospital admission. AIR, Asthma Intervention Research; RISA, Research in Severe Asthma. 
Future opportunities
The majority of patients with asthma can control their disease through compliant use of currently available antiinflammatory and bronchodilating medications. When these measures fail, there are a number of potential explanations that include uncontrolled inflammation, continued bronchoconstriction, and fixed airflow obstruction due to remodeling of the airway wall. Although uncontrolled inflammation may respond to even higher doses of corticosteroids given systemically (pursuing this possibility empirically may lead to excessive steroid prescription), increasingly we find instances where airway inflammation is not adequately treated by steroids. Thus, bronchial thermoplasty may be indicated to address airway muscle accumulation and bronchoconstriction, but so far has not been shown to influence airway inflammation. It follows that appropriate selection of patients for bronchial thermoplasty should include description and optimization of the treatment of their airway inflammation.
Recently, there has been a focus on minimizing potential for hospitalization following bronchial thermoplasty [20 ] . This strategy, however, will exclude patientswith relative resistance to usual medications, established airflow obstruction, and unstable disease -for whom new therapies are most needed. It is likely that once there is broad experience with the technique, the criteria of optimal patient selection will be reexamined in order to explore how to provide bronchial thermoplasty to patients with more severe asthma. In addition to careful description of airway biology and optimal pharmacotherapy, it might be valuable to change how bronchial thermoplasty is delivered, for example, under general anesthetic, or during hospital admission for intensive systemic anti-inflammatory treatment and asthma trigger avoidance.
Conclusion
Despite major advances in understanding mechanisms of asthma and development of improved medical therapies, a number of frustrations remain for our patients. These include the need for daily treatment, the ever-present risk of exacerbation, and the risks associated with escalating doses of steroids. Bronchial thermoplasty can be regarded as the prototype for a new mode of asthma therapy with a number of novel and attractive featuresit targets structural changes in the airway, has long-lasting effects, is unlike any currently available treatment and thus complements standard therapy, and is not restricted to asthma caused by specific pathogenetic events (such as IgE-mediated, or eosinophilic asthma). The development of bronchial thermoplasty prompts us to reconsider our current paradigms for pathogenesis and treatment of asthma, thus stimulating exploration of other novel interventions -perhaps targeting neural, vascular, epithelial cell, or myofibroblast biology [27] .
